Leah R. Neufeld

CIK: 0001950673

Transaction Breakdown

Open Market Buys (P)3 (42.9%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IMRX

Immuneering Corp

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

IMRX
Immuneering Corp
Mar 13, 2026
Award(A)
Direct
3.6K shares at avg. $4.29$16K
IMRX
Immuneering Corp
Feb 3, 2026
Award(A)
Stock Option
Direct
140K shares-
IMRX
Immuneering Corp
Jan 13, 2026
Purchase(P)
Direct
2.6K shares at avg. $4.15$11K
IMRX
Immuneering Corp
Oct 1, 2025
Purchase(P)
Direct
800 shares at avg. $6.38$5K
IMRX
Immuneering Corp
Sep 15, 2025
Award(A)
Direct
11.8K shares at avg. $1.43$17K
IMRX
Immuneering Corp
Jul 2, 2025
Purchase(P)
Direct
700 shares at avg. $3.57$2K
IMRX
Immuneering Corp
Feb 5, 2025
Award(A)
Stock Option
Direct
110K shares-

		Type	Shares	Price		Ownership
Mar 13, 2026	IMRX Immuneering Corp	Award(A)	3,628	$4.29	$15,573	Direct
Feb 3, 2026	IMRX Immuneering Corp	Award(A) Stock Option	140,000	-	-	Direct
Jan 13, 2026	IMRX Immuneering Corp	Purchase(P)	2,626	$4.15	$10,906	Direct
Oct 1, 2025	IMRX Immuneering Corp	Purchase(P)	800	$6.38	$5,103	Direct
Sep 15, 2025	IMRX Immuneering Corp	Award(A)	11,815	$1.43	$16,872	Direct
Jul 2, 2025	IMRX Immuneering Corp	Purchase(P)	700	$3.57	$2,499	Direct
Feb 5, 2025	IMRX Immuneering Corp	Award(A) Stock Option	110,000	-	-	Direct

1-7 of 7 transactions

About Neufeld Leah R

Neufeld Leah R (SEC CIK 0001950673) files insider reports with the SEC as CHIEF PEOPLE OFFICER of Immuneering Corp (IMRX).

Signal8 holds 7 ownership filings by Neufeld Leah R, all Form 4s, filed between Feb 7, 2025 and Mar 17, 2026. Those filings report 7 transactions, from Feb 5, 2025 to Mar 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Neufeld Leah R's filings is in CAMBRIDGE, MA.

Recent filings by Neufeld Leah R

Mar 13, 2026: Grant or award of IMRX shares (Form 4, code A).
Feb 3, 2026: Grant or award of IMRX derivative securities (Form 4, code A).
Jan 13, 2026: Open-market purchase of IMRX shares (Form 4, code P).
Oct 1, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Sep 15, 2025: Grant or award of IMRX shares (Form 4, code A).

Other insiders filing for Immuneering Corp (IMRX)

Gengos Andrew, Chief Financial Officer
Zeskind Benjamin J., PRESIDENT AND CEO
Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
Schall Thomas J., Director
HAUSMAN DIANA, Director
CARPENTER ROBERT J, Director

How to read Form 4 transaction codes